Drugs Made In America Acquisition Corp.

Previous wording

For the three months ended June 30, 2025, we had a net income of $2,288,579, which consists of interest earned on cash and investments held in the trust account of $2,420,498, offset by general and administrative costs of $131,919.

Current wording

For the three months ended September 30, 2025, we had a net income of $2,184,563, which consists of interest earned on cash and investments held in the trust account of $2,448,266, offset by general and administrative costs of $263,703.

Previous wording

For the six months ended June 30, 2025, we had a net income of $3,543,122, which consists of interest earned on cash and investments held in the trust account of $4,005,966, offset by general and administrative costs of $462,844.

Current wording

For the nine months ended September 30, 2025, we had a net income of $5,727,685, which consists of interest earned on cash and investments held in the trust account of $6,454,232, offset by general and administrative costs of $726,547.

Previous wording

For the period from May 23, 2024 (inception) through June 30, 2024, we had a net loss of $54,931, which consists of general and administrative costs.

Current wording

For the period from May 23, 2024 (inception) through September 30, 2024, we had a net loss of $199,859, which consists of general and administrative costs.

Previous wording

As of June 30, 2025, we had cash of $822. Until the consummation of the Initial Public Offering, our only source of liquidity was an initial purchase of ordinary shares by the sponsor and loans from our sponsor.

Current wording

As of September 30, 2025, we had cash of $717. Until the consummation of the Initial Public Offering, our only source of liquidity was an initial purchase of ordinary shares by the sponsor and loans from our sponsor.

Previous wording

On January 29, 2025, we consummated the Initial Public Offering of 20,000,000 Units, at a price of $10.00 per unit, generating gross proceeds of $200,000,000. Simultaneously with the closing of the Initial Public Offering, we consummated the sale of 400,000 Private Placement Units to the sponsor at a price of $10.00 per unit for $4,000,000, of which $1,100,000 was not received and included as share subscription receivable. Since the Initial Public Offering until June 30, 2025, the Sponsor has paid $404,175 in expenses on behalf of the Company (including $50,000 related to the administrative support agreement) affecting the share subscription receivable on the unaudited balance sheet to $695,825. On February 18, 2025, the underwriters exercised their over-allotment option to purchase an additional 3,000,000 Units at a purchase price of $10.00 per Unit, generating additional gross proceeds of $30,000,000. Simultaneously with the sale of the over-allotment Units, the sponsor purchased an additional 30,000 Private Placement Units at a purchase price of $10.00 per unit, generating additional gross proceeds of $300,000.

Current wording

On January 29, 2025, we consummated the Initial Public Offering of 20,000,000 Units, at a price of $10.00 per unit, generating gross proceeds of $200,000,000. Simultaneously with the closing of the Initial Public Offering, we consummated the sale of 400,000 Private Placement Units to the sponsor at a price of $10.00 per unit for $4,000,000, of which $1,100,000 was not received and included as share subscription receivable. Since the Initial Public Offering until September 30, 2025, the Sponsor has paid $491,178 in expenses on behalf of the Company (including $81,000 related to the administrative support agreement) affecting the share subscription receivable on the unaudited balance sheet to $608,822. On February 18, 2025, the underwriters exercised their over-allotment option to purchase an additional 3,000,000 Units at a purchase price of $10.00 per Unit, generating additional gross proceeds of $30,000,000. Simultaneously with the sale of the over-allotment Units, the sponsor purchased an additional 30,000 Private Placement Units at a purchase price of $10.00 per unit, generating additional gross proceeds of $300,000.

Previous wording

On January 29, 2025, we issued a new unsecured subscription promissory note to the sponsor (the “Subscription Promissory Note”) in connection with the amended and restated units purchase agreement pursuant to which we may borrow up to an aggregate principal amount of $1,100,000 working capital loans. The sponsor further agrees that such loans shall be converted into Private Placement Units, at the price of $10.00 per unit. To the extent the amount of such loans is less than $1,100,000, the sponsor acknowledges and agrees that it (or, if applicable, it and any transferees of Private Placement Units) shall surrender for cancellation any and all rights to up to an aggregate of 110,000 Private Placement Units at $10.00 per unit. As of June 30, 2025, there was $695,825 outstanding and reported as share subscription receivable on the unaudited balance sheet.

Current wording

On January 29, 2025, we issued a new unsecured subscription promissory note to the sponsor (the “Subscription Promissory Note”) in connection with the amended and restated units purchase agreement pursuant to which we may borrow up to an aggregate principal amount of $1,100,000 working capital loans. The sponsor further agrees that such loans shall be converted into Private Placement Units, at the price of $10.00 per unit. To the extent the amount of such loans is less than $1,100,000, the sponsor acknowledges and agrees that it (or, if applicable, it and any transferees of Private Placement Units) shall surrender for cancellation any and all rights to up to an aggregate of 110,000 Private Placement Units at $10.00 per unit. As of September 30, 2025, there was $608,822 outstanding and reported as share subscription receivable on the unaudited balance sheet.